Amino acid balance could play a role in SMA, as a study showed acids able to influence nervous system function were ...
The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.
A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.
Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
Japanese drugmaker Chugai (TYO: 4519) has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) ...
A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...
for apitegromab for the improvement of motor functions in patients with spinal muscular atrophy (SMA). Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback